Personalized Medicine Biomarkers Market to reach USD 58.39 billion by 2032 at CAGR of 14.54%
The Personalized Medicine Biomarkers Market is progressing swiftly because of the rising trend toward tailored treatments, propelled by advancements in precision medicine and the heightened need for targeted therapies. Biomarkers allow healthcare providers to customize treatments by pinpointing which patients are most likely to respond well to particular therapies, minimizing negative effects, and enhancing overall treatment results. Oncology continues to be the primary application area, with biomarkers such as PD-L1, BRCA1/2, and EGFR becoming critical for diagnostic and treatment choices.